世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

サマリー

この調査レポートは、世界の製薬企業とバイオ企業の提携関係を分析している。企業提携の促進要因と阻害要因，最近のＭ＆Ａとライセンシングの件数(2009年3月~2010年1月)，ライセンシングの内訳(ライセンシング，商業化，共同開発，2005年~2009年)，企業提携の治療薬分野の内訳(循環器，がんなど科目別，2008年~2010年)と具体的提携内容，企業提携の医薬品開発段階別内訳(発見段階，フェーズ１など，2010年)と具体的提携内容，主要企業の最近の提携事例と企業戦略分析(AstraZeneca，Novartis，Roche，GlaxoSmithKline，Pfizer，Merck，Sanofi-Aventis，Amgen)，企業提携の今後の方向などを記載しています。

Research Overview

This Frost & Sullivan research service titled Global Pharma-Biotech Alliance Analysis provides a detailed analysis of the trends, opportunities, and unmet needs in the decision to enter emerging markets by pharmaceutical companies. In this research, Frost & Sullivan's expert analysts thoroughly examine the following regions: Brazil, Russia, India, and China.

This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.

Market Overview

Pharmaceutical Companies Burdened with High Drug Development Costs Seek Opportunities in Lucrative Emerging Markets

The escalating cost of drug development is driving pharmaceutical companies to tap emerging markets in order to successfully expand and sell their products. Emerging markets are considered lucrative due to their economical infrastructure and labour costs and a significant untapped market potential with a large population. Furthermore, healthcare reform programmes in emerging markets have dramatically improved the level of healthcare coverage in these countries. “With companies focusing on emerging markets, they would need to address the varying medical requirements of each of these markets,” says the analyst of this research. “Therefore, there will be an overall shift in the pharmaceutical industry from a very western centric model to a global one.” Disease areas that were once considered niche are now given priority and the more prevalent disease therapeutic areas in the mature markets have taken a backseat. Vaccines, biologics, over the counter (OTC) candidates, and generics are the principal revenue generators in the emerging markets.

However, weak intellectual property (IP) laws, escalating drug costs, and low reimbursement rates for drugs plague the current healthcare system in China. Implementation of the proposed new plan to invest in emerging economies will go a long way in attracting financial investments from pharmaceutical companies across the globe as the plan intends to pass stringent IP laws and provide healthcare coverage to all. This will create a huge market potential that the pharmaceutical companies can capitalise. “One of the main drawbacks of the Indian pharmaceutical industry is weak IP laws and policies,” explains the analyst. “The new Indian patent code has addressed that and several other issues, yet there remains a clause that disallows patents for treatments that are not more efficacious than those already available.”

Although the emerging markets have several restraints, it does not stop the big pharmaceutical companies from investing in countries like India and China, which offer greater advantages such as intellectual talent pool, cheap land and labour, and investor-friendly governments. “These companies need to re-evaluate their priorities and develop customised strategies that are suitable for the emerging markets,” concludes the analyst.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Region:

• Brazil
• Russia
• India
• China

Frost & Sullivan Growth Partnership Services

Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.

Our growth solutions support the entire growth process:

TEAM Research is a program that furnishes clients with access to market research, competitive intelligence, financial benchmarking, and market strategies and analysis, and provides access to industry experts to aid in generating growth opportunities.

Growth Consulting Services unite clients with our industry experts to evaluate opportunities and develop customized strategies and business plans to drive top-line revenue and margin growth.

Growth Team Membership™ is a career-focused offering that was developed to address the unique challenges that senior executives face when implementing strategies to achieve aggressive corporate growth targets.

目次